Tandem Diabetes Care heads into the back half of August with a notable split in momentum — a 27% one-month rally has prompted fresh analyst attention while short sellers quietly but consistently pare back positions.
The short-covering story is the most significant development in the data this week. Short interest has fallen roughly 14% over the past month, dropping from around 13 million shares to 10.85 million — now equal to 16% of the free float. That is still an elevated absolute level, but the direction is clear: bears have been reducing exposure steadily since early August, when the stock gapped higher following its earnings print. Borrow conditions offer no urgency for further covering. Cost to borrow is running at just 0.53%, barely above its 30-day average, and availability is extraordinarily loose at over 1,000% — meaning there are roughly ten shares available to borrow for every one currently lent out. That is not the profile of a borrow market under any stress. The ORTEX short score has edged down through the week to 56.3, consistent with a position that remains meaningful but is drifting less bearish.
Options positioning has nudged slightly more cautious than usual — though not dramatically so. The put/call ratio climbed to 0.55 on Friday, modestly above its 20-day average of 0.46 and around 0.8 standard deviations above the mean. That is a mild tilt toward protection rather than a clear defensive signal. The 52-week PCR range runs from 0.30 to 1.17, so the current reading sits comfortably in the middle. What the recent PCR history does show is a meaningful shift: through July and into early August, the ratio was running in the low 0.33 range, reflecting heavy call dominance during the stock's run-up. The modest rise since then likely reflects some profit-taking on calls rather than any fresh bearish positioning.
The Street has grown more constructive in recent weeks, though with notable nuance. William Blair initiated coverage with an Outperform rating on Friday — the most recent action. Following the August 6 earnings release, Citigroup raised its target from $17 to $21 while holding Neutral, and RBC Capital trimmed its target from $30 to $26 but kept its Outperform rating. The direction of travel from the bulls is clear: the earnings print was better than feared, but near-term valuation discipline is tightening. The bears on the Street — Citigroup, UBS, Mizuho, Deutsche Bank — all sit at Neutral or Hold, with targets clustered in the $18–$21 range. Wells Fargo's upgrade to Overweight from June, with a $27 target, remains the most optimistic published view. Against a current price of $22.32, the consensus 11 Buy ratings represent a modest implied upside overall. The EV/EBITDA multiple of 18.5x has compressed about 0.6 turns over the past month, suggesting the re-rating from the earnings pop is starting to stabilise. The company carries a negative P/E given it has not yet reached profitability, with the EPS earnings yield running at roughly -0.6%.
The August 6 earnings reaction provides crucial context for how this stock behaves around catalysts. The print triggered a 14.2% one-day move and a further 18.1% gain over the subsequent five days — one of the sharper post-earnings reactions in the medtech space. The prior quarter produced a 7% one-day decline before recovering 16% over five days. The pattern suggests the stock is highly reactive to earnings surprises in both directions. Bulls argue that the insulin pump differentiation story and the overseas renewal cycle support consistent double-digit revenue growth. Bears point to supplier concentration risk, reimbursement uncertainty, and the company's ongoing pre-profitability status as reasons to stay cautious on valuation. With the next earnings event not until November 4, the near-term focus shifts to whether the stock can hold its post-earnings gains — and whether the institutional buying evident in BlackRock's addition of 892,000 shares and First Light's build of over 2 million shares is a signal that larger holders are committing to the thesis at these levels.
What to watch: how short interest behaves if the stock consolidates around current levels, and whether the analyst target distribution — still skewed below the current price on the neutral side — begins to migrate upward if commercial execution holds through Q3.
See the live data behind this article on ORTEX.
Open TNDM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
